SLC5A5 and cancer: As illustrated in Fig. 2(A), stronger NIS immunostaining was observed at the plasma membrane of the cancer cells that are located at the border of the tumors (Fig. 2(D)) and that exhibit higher mitotic activity (Ki-67) (Fig. 2(B) and (F)).